Diazoxide Choline Designated Breakthrough Therapy for Prader

Diazoxide Choline Designated Breakthrough Therapy for Prader-Willi Syndrome

The FDA has granted Breakthrough Therapy designation to diazoxide choline for the treatment of adults and children ages 4 years and older with genetically confirmed Prader-Willi syndrome (PWS) who have hyperphagia.

Related Keywords

Manish Bhatnagar , Drug Administration , Breakthrough Therapy , Fast Track ,

© 2025 Vimarsana